Clinical studies, IHC: Wright et al. performed immuno-peroxidase staining for PSMA reactivity on prostate carcinoma specimens from 20 prostate carcinoma patients who matched pre-treatment and post-treatment (treatment consisting of medical or surgical castration or combination androgen deprivation therapy); specimens were available as well on specimens from 16 patients that were obtained post-treatment (5 from primary and 11 from metastatic lesions) [42]. The gene discussed is FOLH1; the disease is prostate carcinoma.